These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. Naber D; Greenspan A; Schreiner A Psychopharmacology (Berl); 2007 May; 191(4):1027-9. PubMed ID: 17333131 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935 [TBL] [Abstract][Full Text] [Related]
6. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G; Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797 [TBL] [Abstract][Full Text] [Related]
7. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Melkersson KI Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165 [TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618 [TBL] [Abstract][Full Text] [Related]
9. Nursing home research from industry's perspective. Brecher M Int Psychogeriatr; 1996; 8 Suppl 3():367-70. PubMed ID: 9154590 [No Abstract] [Full Text] [Related]
10. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. Nair NP J Clin Psychopharmacol; 1998 Apr; 18(2):103-10. PubMed ID: 9555595 [TBL] [Abstract][Full Text] [Related]
11. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871 [TBL] [Abstract][Full Text] [Related]
12. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779 [TBL] [Abstract][Full Text] [Related]
13. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
14. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192 [TBL] [Abstract][Full Text] [Related]
15. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. Ouyang WC; Hsu MC; Yeh IN; Kuo CC Int J Psychiatry Clin Pract; 2012 Sep; 16(3):178-88. PubMed ID: 22404731 [TBL] [Abstract][Full Text] [Related]
17. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Klampfl K; Taurines R; Preuss A; Burger R; Rothenhöfer S; Wewetzer Ch; Pfuhlmann B; Fegert J; Gerlach M; Mehler-Wex C Pharmacopsychiatry; 2010 Mar; 43(2):58-65. PubMed ID: 20336598 [TBL] [Abstract][Full Text] [Related]
18. Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital. Advokat C; Dixon D; Schneider J; Comaty JE Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):487-95. PubMed ID: 15093956 [TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Aman MG; Vinks AA; Remmerie B; Mannaert E; Ramadan Y; Masty J; Lindsay RL; Malone K Clin Ther; 2007 Jul; 29(7):1476-86. PubMed ID: 17825699 [TBL] [Abstract][Full Text] [Related]
20. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P Am J Psychiatry; 1998 Apr; 155(4):499-504. PubMed ID: 9545995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]